{"key":"retatrutide","slug":"retatrutide","name":"Retatrutide","other_names":["LY3437943","Reta"],"kind":"single","area":{"slug":"metabolic","name":"Metabolic"},"classification":"Triple GIP, GLP-1 and glucagon receptor agonist","standing":{"id":"phase-3","label":"Phase 3 trials","rank":4},"summary":"A single peptide engineered to act on three receptors at once: GIP, GLP-1 and glucagon. Its trials in obesity, type 2 diabetes and liver fat run to phase 3, and it is still investigational.","cas_number":"2381089-83-2","molecular_formula":"C221H342N46O68","molecular_weight":"4731.4 g/mol","components":[],"has_article":true,"pubmed":{"papers":219,"in_humans":133,"clinical_trials":12},"retired":false,"updated_at":"2026-11-16T12:00:00.000Z","url":"https://pepts.wiki/compounds/retatrutide","article":{"developer":"Eli Lilly and Company","standing_note":"Investigational. The phase 3 report published in 2026 describes retatrutide as under clinical development for type 2 diabetes, obesity and related complications; no source here records a marketing authorization [4].","facts":[{"label":"Developer code","value":"LY3437943","source":6},{"label":"Receptors","value":"GIP, GLP-1 and glucagon","source":6},{"label":"Half-life","value":"About 6 days","source":5},{"label":"Route in trials","value":"Subcutaneous injection, once weekly","source":1},{"label":"Weekly amounts in trials","value":"0.5 mg to 12 mg","source":2},{"label":"Most reported adverse events","value":"Gastrointestinal: nausea, diarrhea, vomiting, constipation","source":2},{"label":"Furthest trial","value":"Phase 3 (TRANSCEND-T2D-1)","source":4},{"label":"Trials funded by","value":"Eli Lilly and Company","source":1}],"takeaways":["Retatrutide, first published as LY3437943, is one peptide with agonist activity at the GIP, GLP-1 and glucagon receptors [1], [6].","In the phase 2 obesity trial, 338 adults received once-weekly injections for 48 weeks. The mean change in body weight was -24.2% on 12 mg against -2.1% on placebo [1].","In type 2 diabetes, HbA1c fell by 2.02 percentage points on 12 mg at 24 weeks in the phase 2 trial, and by 1.94 percentage points at 40 weeks in the phase 3 trial TRANSCEND-T2D-1 [2], [4].","In the liver fat substudy, the mean relative change in liver fat at 24 weeks was -82.4% on 12 mg against +0.3% on placebo, and 86% of that group reached normal liver fat [3].","Gastrointestinal events were the most common adverse events, mostly mild to moderate and dose related. The longest published trial ran 48 weeks [1], [4]."],"receptors":[{"name":"GIP receptor","role":"In vitro the molecule is more active here than at the other two receptors. In obese mice the discovery paper credits GIP and GLP-1 receptor activity with the reduction in calorie intake [6].","short":"GIP"},{"name":"GLP-1 receptor","role":"Activity here is balanced with activity at the glucagon receptor in vitro. Together with GIP it is credited with lower calorie intake in obese mice [6].","short":"GLP-1"},{"name":"Glucagon receptor","role":"The receptor the earlier dual agonists do not act on. In obese mice, weight loss was augmented by glucagon receptor-mediated increases in energy expenditure [6]. A review calls the added benefit from this receptor largely unexpected [8].","short":"GCG"}],"sections":[{"id":"what-it-is","body":["Retatrutide is a single peptide, first published under the developer code LY3437943, engineered to act as an **agonist** at three receptors at once: the glucose-dependent insulinotropic polypeptide (**GIP**) receptor, the glucagon-like peptide 1 (**GLP-1**) receptor and the **glucagon** receptor [1], [6]. The trial reports call it a triple hormone receptor agonist and describe it as under clinical development for type 2 diabetes, obesity and related complications [4].","It sits at the end of a sequence that a review of islet mechanisms describes: the known actions of GLP-1 and of GIP alone, then single molecules that activate both incretin receptors, and now triple agonism with molecules that also bind the glucagon receptor [8]. Eli Lilly funded the phase 1b, phase 2 and phase 3 trials described on this page and sponsors the studies registered under its name [1], [2], [4], [10]."],"title":"What retatrutide is"},{"id":"mechanism","body":["Each of the three receptors is credited with a different part of the effect. In obese mice, the discovery paper attributes the reduction in calorie intake to GIP and GLP-1 receptor activity and reports that body weight loss was augmented by glucagon receptor-mediated increases in energy expenditure [6]. In vitro, the molecule's activity at the glucagon and GLP-1 receptors is balanced while its GIP receptor activity is greater [6].","What each receptor does inside the pancreatic islet is less settled. A scoping review of dual and triple agonists reports that the additive insulin-releasing effects of GLP-1 and GIP receptor agonism were anticipated from the known actions of each hormone alone, while the additional benefit from the glucagon receptor was largely unexpected [8].","The pharmacokinetics are what allow a once-weekly injection in the trials. In the phase 1 single ascending dose study reported in the discovery paper, a reduction in body weight persisted up to day 43 after a single dose [6]. In the phase 1b trial in adults with type 2 diabetes, exposure was dose proportional and the half-life was approximately 6 days [5]."],"note":{"text":"Whether the three signaling pathways interact synergistically or antagonistically when they are stimulated together is, in the review's own words, not known. Its authors write that this knowledge will be essential for understanding the chronic efficacy and long-term safety of these treatments [8].","title":"What the mechanism review leaves open"},"title":"How it works"},{"id":"obesity","body":["The phase 2 obesity trial is the one most people mean when they quote retatrutide's results. It enrolled adults with a body-mass index of 30 or higher, or of 27 to less than 30 with at least one weight-related condition, and randomized them to once-weekly subcutaneous retatrutide at 1 mg, 4 mg, 8 mg or 12 mg, or placebo, for 48 weeks. The 4 mg and 8 mg groups were each split by starting dose, 2 mg or 4 mg [1]. Of the 338 adults enrolled, 51.8% were men [1].","The primary end point was the percentage change in body weight from baseline to 24 weeks. At that point the least-squares mean change was -7.2% on 1 mg, -12.9% in the combined 4 mg group, -17.3% in the combined 8 mg group and -17.5% on 12 mg, against -1.6% on placebo [1]. At 48 weeks, a secondary end point, the figures were -8.7%, -17.1%, -22.8% and -24.2% by dose, against -2.1% on placebo [1].","By 48 weeks, a weight reduction of 5% or more, 10% or more and 15% or more had occurred in 92%, 75% and 60% of those on 4 mg; 100%, 91% and 75% of those on 8 mg; 100%, 93% and 83% of those on 12 mg; and 27%, 9% and 2% of those on placebo [1].","A 2025 systematic review and meta-analysis pooled four randomized controlled trials of retatrutide against placebo and reports a dose-dependent relationship, with the 12 mg dose producing the largest reductions across every outcome considered. The same authors describe the trials they pooled as preliminary and write that they await further trials for more robust results [7]."],"title":"The phase 2 obesity trial"},{"id":"type-2-diabetes","body":["The phase 1b trial enrolled 72 adults with type 2 diabetes at four centers in the USA and followed them for 12 weeks across five ascending dose cohorts [5]. Placebo-adjusted HbA1c fell significantly in the three highest dose groups, by 1.4% on 3 mg, 1.6% on 3/6 mg and 1.2% on 3/6/9/12 mg, and placebo-adjusted body weight reduction appeared dose dependent, up to 8.96 kg in the highest cohort [5].","The phase 2 trial that followed enrolled 281 adults aged 18 to 75 with type 2 diabetes and an HbA1c of 7.0% to 10.5% at 42 centers in the USA. They were randomized to once-weekly placebo, dulaglutide 1.5 mg, or retatrutide at 0.5 mg, 4 mg, 8 mg or 12 mg [2]. At 24 weeks the change in HbA1c was -0.43% on 0.5 mg, -1.39% and -1.30% in the two 4 mg groups, -1.99% and -1.88% in the two 8 mg groups and -2.02% on 12 mg, against -0.01% on placebo and -1.41% on dulaglutide [2].","Body weight decreased dose dependently at 36 weeks: by 3.19% on 0.5 mg, 7.92% and 10.37% in the two 4 mg groups, 16.81% and 16.34% in the two 8 mg groups and 16.94% on 12 mg, against 3.00% on placebo and 2.02% on dulaglutide [2].","A phase 3 result, TRANSCEND-T2D-1, was published in 2026: a 40-week, randomized, double-blind, placebo-controlled trial at 48 sites in the USA, Mexico and India in adults with type 2 diabetes inadequately controlled by diet and exercise alone [4]. In total 537 adults were randomized to retatrutide 4 mg, 9 mg or 12 mg or placebo. The mean change in HbA1c from baseline to week 40 was -1.69%, -1.86% and -1.94% by dose against -0.81% on placebo, and the mean change in body weight was -11.5%, -13.9% and -15.3% against -2.6% [4]."],"note":{"text":"The obesity trial selected adults on body-mass index and the diabetes trials on HbA1c, so their weight figures sit beside each other rather than on one curve: -24.2% at 48 weeks in the obesity trial, a 16.94% decrease at 36 weeks in the phase 2 diabetes trial and -15.3% at 40 weeks in the phase 3 trial, all on 12 mg [1], [2], [4].","title":"Two populations, read side by side"},"title":"Type 2 diabetes: phase 1b to phase 3"},{"id":"liver-fat","body":["Of the 338 adults randomized in the phase 2 obesity trial, 98 had metabolic dysfunction-associated steatotic liver disease (**MASLD**) with liver fat of 10% or more on magnetic resonance imaging, and they formed a randomized, double-blind, placebo-controlled substudy of their own [3].","At 24 weeks the mean relative change in liver fat was -42.9% on 1 mg, -57.0% on 4 mg, -81.4% on 8 mg and -82.4% on 12 mg, against +0.3% on placebo, every dose significant against placebo [3]. Normal liver fat, defined as less than 5%, was reached by 27%, 52%, 79% and 86% of participants by dose, and by none of those on placebo [3].","The paper states its own limits: fewer participants had liver fat data at week 48 (43.9%) than at week 24 (78.6%), and 58% of the placebo group completed the substudy against 77% to 90% of the retatrutide groups [3]."],"title":"Liver fat: the MASLD substudy"},{"id":"adverse-events","body":["In the phase 1b, phase 2 obesity and phase 3 diabetes trials, gastrointestinal events were the most frequent adverse events [1], [4], [5]. In the phase 2 obesity trial they were dose related, mostly mild to moderate in severity, and partially mitigated in the arms whose first dose was 2 mg rather than 4 mg. Heart rate rose in a dose-dependent way, peaked at 24 weeks and declined thereafter [1].","In the phase 2 diabetes trial, mild-to-moderate gastrointestinal adverse events, including nausea, diarrhea, vomiting and constipation, were reported by 67 (35%) of the 190 participants on retatrutide, against six (13%) of 45 on placebo and 16 (35%) of 46 on dulaglutide. There were no reports of severe hypoglycemia and no deaths [2].","In the phase 3 trial the most frequent adverse events with retatrutide were again generally mild to moderate gastrointestinal events, which the authors report subsided over time. Discontinuation of the study intervention because of adverse events was 2% to 5% with retatrutide and 0% with placebo. Two deaths occurred during the study, both in the retatrutide 4 mg group, and the paper reports both as unrelated to the study drug [4]."],"note":{"text":"These are the adverse events recorded in trials whose participants were screened against entry criteria, given the compound by investigators and monitored throughout, and the longest of them ran for 48 weeks [1], [3]. The mechanisms review notes that the long-term safety of dual and triple agonists is still to be understood [8].","title":"What these numbers are, and are not"},"title":"What the trials reported as adverse events"},{"id":"where-it-stands","body":["Retatrutide is investigational. The phase 3 report describes it as under clinical development for type 2 diabetes, obesity and related complications [4]. No source on this page records a license application or an authorization, and nothing here describes a use outside a registered trial [10], [11], [12].","ClinicalTrials.gov lists further studies sponsored by Eli Lilly: one of about 77 weeks in participants with obesity or overweight and osteoarthritis of the knee, listed as completed, and one of about 89 weeks comparing retatrutide with tirzepatide in adults with obesity, listed as active and no longer recruiting [11], [12].","TRANSCEND-CKD, whose design and baseline characteristics were published in 2026, is a double-blind, placebo-controlled phase 2b study in 146 adults with overweight or obesity and chronic kidney disease. Its authors say it is designed to inform the ongoing cardio-kidney outcome trial TRIUMPH-Outcomes [9]."],"title":"Where it stands, and what comes next"}],"human_studies":[{"name":"Multiple ascending dose","phase":"Phase 1b","weeks":12,"source":5,"finding":"Half-life approximately 6 days; placebo-adjusted HbA1c down 1.2 to 1.6 points in the three highest groups; placebo-adjusted weight reduction up to 8.96 kg","regimen":"Once-weekly subcutaneous injection in five ascending cohorts, the highest stepping 3, 6, 9 then 12 mg; placebo and dulaglutide 1.5 mg as comparators","population":"Adults aged 20 to 70 with type 2 diabetes, USA","participants":72},{"name":"Obesity","phase":"Phase 2","weeks":48,"source":1,"finding":"Body weight -24.2% on 12 mg against -2.1% on placebo at 48 weeks","regimen":"Once-weekly subcutaneous 1 mg, 4 mg, 8 mg or 12 mg, or placebo; the 4 mg and 8 mg arms started at 2 mg or 4 mg","population":"Adults with a BMI of 30 or higher, or 27 to under 30 with a weight-related condition","participants":338},{"name":"Type 2 diabetes","phase":"Phase 2","weeks":36,"source":2,"finding":"HbA1c -2.02 points on 12 mg at 24 weeks against -0.01 on placebo and -1.41 on dulaglutide; body weight down 16.94% at 36 weeks","regimen":"Once-weekly 0.5 mg, 4 mg, 8 mg or 12 mg, placebo, or dulaglutide 1.5 mg","population":"Adults aged 18 to 75 with type 2 diabetes and HbA1c of 7.0% to 10.5%, USA","participants":281},{"name":"MASLD substudy","phase":"Phase 2a","weeks":48,"source":3,"finding":"Liver fat -82.4% on 12 mg against +0.3% on placebo at 24 weeks; 86% reached normal liver fat","regimen":"Once-weekly 1 mg, 4 mg, 8 mg or 12 mg, or placebo","population":"Participants of the obesity trial with liver fat of 10% or more on MRI","participants":98},{"name":"TRANSCEND-T2D-1","phase":"Phase 3","weeks":40,"source":4,"finding":"HbA1c -1.94 points and body weight -15.3% on 12 mg, against -0.81 points and -2.6% on placebo","regimen":"Once-weekly 4 mg, 9 mg or 12 mg, or placebo","population":"Adults with type 2 diabetes not controlled by diet and exercise; USA, Mexico and India","participants":537},{"name":"TRANSCEND-CKD","phase":"Phase 2b","weeks":24,"source":9,"finding":"Design and baseline published; no results yet","regimen":"Once-weekly at the maximum tolerated dose up to 12 mg, or placebo","population":"Adults with overweight or obesity and chronic kidney disease","participants":146}],"charts":[{"id":"weight-48","unit":"%","title":"Change in body weight at 48 weeks","points":[{"label":"Placebo","value":-2.1,"control":true},{"label":"1 mg","value":-8.7},{"label":"4 mg","value":-17.1},{"label":"8 mg","value":-22.8},{"label":"12 mg","value":-24.2}],"source":1,"caption":"Least-squares mean percentage change from baseline in the phase 2 obesity trial, 338 adults. The 4 mg and 8 mg figures pool two arms that differed only in starting dose.","section":"obesity"},{"id":"hba1c-24","unit":" pts","title":"Change in HbA1c at 24 weeks","points":[{"label":"Placebo","value":-0.01,"control":true},{"label":"Dulaglutide 1.5 mg","value":-1.41,"control":true},{"label":"0.5 mg","value":-0.43},{"label":"4 mg, escalated","value":-1.39},{"label":"4 mg","value":-1.3},{"label":"8 mg, slow","value":-1.99},{"label":"8 mg, fast","value":-1.88},{"label":"12 mg","value":-2.02}],"source":2,"caption":"Least-squares mean change in percentage points in the phase 2 trial in 281 adults with type 2 diabetes. The two 4 mg and two 8 mg arms differed in how the dose was escalated.","section":"type-2-diabetes"},{"id":"liver-24","unit":"%","title":"Relative change in liver fat at 24 weeks","points":[{"label":"Placebo","value":0.3,"control":true},{"label":"1 mg","value":-42.9},{"label":"4 mg","value":-57},{"label":"8 mg","value":-81.4},{"label":"12 mg","value":-82.4}],"source":3,"caption":"Mean relative change from baseline in the MASLD substudy, 98 participants with liver fat of 10% or more.","section":"liver-fat"}],"timeline":[{"what":"The phase 1b trial in type 2 diabetes begins enrolling in December, at four centers in the USA [5].","when":"2019"},{"what":"The phase 2 obesity trial is registered and randomizes its first participants; the phase 2 diabetes trial begins [2], [10].","when":"2021"},{"what":"The discovery paper and the phase 1b results are published under the code LY3437943 [5], [6].","when":"2022"},{"what":"The phase 2 results in obesity and in type 2 diabetes are published [1], [2].","when":"2023"},{"what":"The MASLD substudy is published; TRANSCEND-T2D-1 begins randomizing; a head-to-head trial against tirzepatide is registered [3], [4], [12].","when":"2024"},{"what":"A systematic review and meta-analysis pools four placebo-controlled trials [7].","when":"2025"},{"what":"The TRANSCEND-T2D-1 results and the TRANSCEND-CKD design paper are published [4], [9].","when":"2026"}],"handling":{"form":"Lyophilized powder in a sealed vial","notes":["**Reconstitution** is adding a diluent back to a lyophilized product so that it dissolves into a solution again [13]. The arithmetic needs no source: concentration is the mass in the vial divided by the volume added, and the volume that holds a given mass is that mass divided by the concentration.","**Bacteriostatic water** is water for injection carrying 0.9% benzyl alcohol as an antimicrobial preservative. A formulation review reports that multi-dose biological products require a preservative to avoid microbial growth, and that the same preservative can speed protein aggregation [13].","Bulking agents give a lyophilized cake its mechanical strength and its porous structure [14].","The preset amounts in the calculator are the weekly amounts the phase 2 protocols assigned to trial arms [1], [2]. They are shown so the arithmetic can be checked against the published studies, and are not a recommendation of any kind."],"vialMg":[10,20,30,40,50,60],"storage":{"lyophilized":"General practice for lyophilized peptides is to keep the sealed vial frozen or refrigerated, dry and away from light, and to follow the supplier's certificate of analysis. The trial reports do not describe how retatrutide's own trial supply was stored.","reconstituted":"Once a peptide is back in solution it is kept refrigerated and used within the period the supplier states. A vial that will be drawn from more than once needs a preserved diluent [13]."},"sampleUg":[500,1000,2000,4000,8000,12000],"diluentMl":[1,2,3]},"faq":[{"a":"Yes. The discovery paper describes LY3437943 as a triple agonist at the glucagon, GIP and GLP-1 receptors, with balanced glucagon and GLP-1 receptor activity and more GIP receptor activity in vitro [6].","q":"Is retatrutide a triple agonist?"},{"a":"In 338 adults with obesity or overweight, once-weekly retatrutide for 48 weeks produced mean changes in body weight of -8.7%, -17.1%, -22.8% and -24.2% at 1 mg, 4 mg, 8 mg and 12 mg, against -2.1% on placebo. Gastrointestinal events were the most common adverse events [1].","q":"What did the phase 2 obesity trial show?"},{"a":"The trial reports place retatrutide beside two earlier classes, GLP-1 receptor agonists and dual GIP and GLP-1 receptor agonists. It differs from both by adding agonist activity at the glucagon receptor [2], [8]. A registered trial of about 89 weeks is comparing it directly with tirzepatide in adults with obesity [12].","q":"How does retatrutide differ from semaglutide and tirzepatide?"},{"a":"No trial report cited here describes a licensed product: all describe a compound under clinical development for type 2 diabetes, obesity and related complications [4], [5].","q":"Is retatrutide approved?"},{"a":"Approximately 6 days, measured in the phase 1b trial in adults with type 2 diabetes, where the pharmacokinetics were dose proportional and the authors concluded that they suited once-weekly dosing [5].","q":"What is the half-life of retatrutide?"},{"a":"The phase 2 trials assigned once-weekly subcutaneous amounts of 0.5 mg, 1 mg, 4 mg, 8 mg or 12 mg, with some arms starting at 2 mg or 4 mg and stepping up [1], [2]. The phase 3 trial in type 2 diabetes assigned 4 mg, 9 mg or 12 mg [4]. These are what protocols assigned to screened and monitored participants, not guidance for anyone else.","q":"What amounts did the trials use?"}],"sources":[{"n":1,"doi":"10.1056/nejmoa2301972","url":"https://doi.org/10.1056/nejmoa2301972","kind":"rct","pmid":"37366315","year":2023,"title":"Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial","venue":"The New England Journal of Medicine","authors":"Jastreboff AM, Kaplan LM, Frías JP, et al."},{"n":2,"doi":"10.1016/s0140-6736(23)01053-x","url":"https://doi.org/10.1016/s0140-6736(23)01053-x","kind":"rct","pmid":"37385280","year":2023,"title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","venue":"The Lancet","authors":"Rosenstock J, Frias J, Jastreboff AM, et al."},{"n":3,"doi":"10.1038/s41591-024-03018-2","url":"https://doi.org/10.1038/s41591-024-03018-2","kind":"rct","pmid":"38858523","year":2024,"title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","venue":"Nature Medicine","authors":"Sanyal AJ, Kaplan LM, Frias JP, et al."},{"n":4,"doi":"10.1016/s0140-6736(26)00967-0","url":"https://doi.org/10.1016/s0140-6736(26)00967-0","kind":"rct","pmid":"42250575","year":2026,"title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","venue":"The Lancet","authors":"Bajaj HS, Welch M, Shah P, et al."},{"n":5,"doi":"10.1016/s0140-6736(22)02033-5","url":"https://doi.org/10.1016/s0140-6736(22)02033-5","kind":"rct","pmid":"36354040","year":2022,"title":"LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial","venue":"The Lancet","authors":"Urva S, Coskun T, Loh MT, et al."},{"n":6,"doi":"10.1016/j.cmet.2022.07.013","url":"https://doi.org/10.1016/j.cmet.2022.07.013","kind":"preclinical","pmid":"35985340","year":2022,"title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept","venue":"Cell Metabolism","authors":"Coskun T, Urva S, Roell WC, et al."},{"n":7,"doi":"10.1080/17512433.2025.2450254","url":"https://doi.org/10.1080/17512433.2025.2450254","kind":"meta","pmid":"39817343","year":2025,"title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis","venue":"Expert Review of Clinical Pharmacology","authors":"Tewari J, Qidwai KA, Tewari A, et al."},{"n":8,"doi":"10.1152/ajpendo.00236.2023","url":"https://doi.org/10.1152/ajpendo.00236.2023","kind":"review","pmid":"37729025","year":2023,"title":"Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets","venue":"American Journal of Physiology. Endocrinology and Metabolism","authors":"Folli F, Finzi G, Manfrini R, et al."},{"n":9,"doi":"10.1093/ndt/gfaf230","url":"https://doi.org/10.1093/ndt/gfaf230","kind":"trial","pmid":"41160422","year":2026,"title":"Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease","venue":"Nephrology Dialysis Transplantation","authors":"Heerspink HJL, van Raalte DH, Bjornstad P, et al."},{"n":10,"nct":"NCT04881760","url":"https://clinicaltrials.gov/study/NCT04881760","kind":"regulator","year":2021,"title":"A Study of LY3437943 in Participants Who Have Obesity or Are Overweight","venue":"ClinicalTrials.gov","authors":"Eli Lilly and Company"},{"n":11,"nct":"NCT05931367","url":"https://clinicaltrials.gov/study/NCT05931367","kind":"regulator","year":2023,"title":"A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee","venue":"ClinicalTrials.gov","authors":"Eli Lilly and Company"},{"n":12,"nct":"NCT06662383","url":"https://clinicaltrials.gov/study/NCT06662383","kind":"regulator","year":2024,"title":"A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity","venue":"ClinicalTrials.gov","authors":"Eli Lilly and Company"},{"n":13,"doi":"10.3390/pharmaceutics15020563","url":"https://doi.org/10.3390/pharmaceutics15020563","kind":"review","pmid":"36839885","year":2023,"title":"Antimicrobial Preservatives for Protein and Peptide Formulations: An Overview","venue":"Pharmaceutics"},{"n":14,"doi":"10.3390/pharmaceutics17101328","url":"https://doi.org/10.3390/pharmaceutics17101328","kind":"review","pmid":"41155963","year":2025,"title":"Short Peptides as Excipients in Parenteral Protein Formulations: A Mini Review","venue":"Pharmaceutics"}],"related":["tirzepatide","semaglutide","cagrilintide","survodutide","mazdutide","retatrutide-cagrilintide"],"reviewed":null},"evidence":{"query":"(retatrutide[tiab] OR LY3437943[tiab])","fetched_at":"2026-11-16T23:06:14.678Z","counts":{"rcts":11,"human":133,"total":219,"reviews":136,"clinicalTrials":12},"years":[{"year":2012,"count":0},{"year":2013,"count":0},{"year":2014,"count":0},{"year":2015,"count":0},{"year":2016,"count":0},{"year":2017,"count":0},{"year":2018,"count":0},{"year":2019,"count":0},{"year":2020,"count":0},{"year":2021,"count":0},{"year":2022,"count":2},{"year":2023,"count":17},{"year":2024,"count":45},{"year":2025,"count":59},{"year":2026,"count":111}],"top":[{"doi":"10.1056/NEJMoa2301972","url":"https://pubmed.ncbi.nlm.nih.gov/37366315/","kind":"rct","pmid":"37366315","year":2023,"title":"Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial","venue":"The New England journal of medicine","authors":"Jastreboff AM, Kaplan LM, Frías JP, et al."},{"doi":"10.1056/NEJMoa2604169","url":"https://pubmed.ncbi.nlm.nih.gov/42814954/","kind":"rct","pmid":"42814954","year":2026,"title":"Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity","venue":"The New England journal of medicine","authors":"Jastreboff AM, Kaplan LM, Davies MJ, et al."},{"doi":"10.1016/S0140-6736(26)00967-0","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","kind":"rct","pmid":"42250575","year":2026,"title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","venue":"Lancet (London, England)","authors":"Bajaj HS, Welch M, Shah P, et al."},{"doi":"10.1016/S0140-6736(23)01053-X","url":"https://pubmed.ncbi.nlm.nih.gov/37385280/","kind":"rct","pmid":"37385280","year":2023,"title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","venue":"Lancet (London, England)","authors":"Rosenstock J, Frias J, Jastreboff AM, et al."},{"doi":"10.1038/s41591-024-03018-2","url":"https://pubmed.ncbi.nlm.nih.gov/38858523/","kind":"rct","pmid":"38858523","year":2024,"title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","venue":"Nature medicine","authors":"Sanyal AJ, Kaplan LM, Frias JP, et al."},{"doi":"10.1515/jbcpp-2025-0113","url":"https://pubmed.ncbi.nlm.nih.gov/40728138/","kind":"review","pmid":"40728138","year":2025,"title":"Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials","venue":"Journal of basic and clinical physiology and pharmacology","authors":"Misra S, Narayan RK, Kaur M"},{"doi":"10.3390/biom15060796","url":"https://pubmed.ncbi.nlm.nih.gov/40563436/","kind":"review","pmid":"40563436","year":2025,"title":"Retatrutide-A Game Changer in Obesity Pharmacotherapy","venue":"Biomolecules","authors":"Katsi V, Koutsopoulos G, Fragoulis C, et al."},{"doi":"10.1080/08998280.2025.2456441","url":"https://pubmed.ncbi.nlm.nih.gov/40291085/","kind":"review","pmid":"40291085","year":2025,"title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials","venue":"Proceedings (Baylor University. Medical Center)","authors":"Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, et al."}]},"library_version":"183:2026-11-17T11:05:42.386Z","attribution":"Data from Pepts.wiki (https://pepts.wiki), CC BY 4.0. Link back to the compound's page.","notice":"We are not doctors, and nothing on Pepts.wiki is medical advice or a recommendation to use anything. The wiki sets out what studies measured, as clearly and evenly as it can, so you can make better-informed decisions. Always consult a medical professional before acting on anything you read here."}